1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Melanoma Therapeutics Market 2015-2019

Global Melanoma Therapeutics Market 2015-2019

  • April 2015
  • -
  • Infiniti Research Limited
  • -
  • 67 pages

About Melanoma
According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years.

TechNavio's analysts forecast the Global Melanoma Therapeutics market to grow at a CAGR of 15.40 percent over the period 2014-2019.


Covered in this Report
This report covers the present scenario and the growth prospects of the Global Melanoma Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of melanoma that are available in the market. The market is divided into four segments: CM, OM, MM, and Others.

TechNavio's report, Global Melanoma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.


Key Regions
• Americas
• APAC
• EMEA


Key Vendors
• BMS
• Merck
• Roche

Other Prominent Vendors
• AB Science
• Amgen
• Bayer
• Celgene
• Daiichi Sankyo
• Eisai
• Galectin Therapeutics
• GSK
• Novartis
• Pfizer
• Vical
• ZIOPHARM


Market Driver
• Increase in Prevalence of Melanoma
• For a full, detailed list, view our report


Market Challenge
• Availability of Alternative Treatments
• For a full, detailed list, view our report


Market Trend
• Emergence of Combination Therapies
• For a full, detailed list, view our report


Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Melanoma Therapeutics Market 2015-2019
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
3.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.3 Key Statistics
06.4 Stages
06.5 Symptoms
06.6 Checklist of Melanoma
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Melanoma Therapeutics Market in US
07.3.1 Market Size and Forecast
07.4 Melanoma Therapeutics Market in UK
07.4.1 Market Size and Forecast
07.5 Melanoma Therapeutics Market in Japan
07.5.1 Market Size and Forecast
07.6 Five Forces Analysis
08. Melanoma Pipeline Landscape
08.1 Key Emerging Pipeline Molecules
09. Market Segmentation by Category
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 BMS
18.2.2 Merck
18.2.3 Roche
18.2.4 Others
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Bristol-Myers Squibb
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Key Product Offerings
19.1.4 Revenue by Geography
19.1.5 Business Strategy
19.1.6 Key Information
19.1.7 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 Merck
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Business Strategy
19.3.7 Key Developments
19.3.8 SWOT Analysis
20. Other Reports in this Series


List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Change of Appearance in Skin Moles: Suspicion of Melanoma
Exhibit 3: New Diagnosed Cases of Melanoma 2012
Exhibit 4: Stages of Melanoma
Exhibit 5: Checklist of Melanoma
Exhibit 6: Snapshot of Global Melanoma Therapeutics Market 2014
Exhibit 7: Global Melanoma Therapeutics Market 2014-2019 (US$ million)
Exhibit 8: Melanoma Therapeutics Market in US 2014-2019 (US$ million)
Exhibit 9: Melanoma Therapeutics Market in UK 2014-2019 (US$ million)
Exhibit 10: Melanoma Therapeutics Market in Japan 2014-2019 (US$ million)
Exhibit 11: Segmentation of Global Melanoma Therapeutics Market by Category
Exhibit 12: Segmentation of Global Melanoma Therapeutics Market by Category
Exhibit 13: Segmentation of Global Melanoma Therapeutics Market by Geography 2014
Exhibit 14: Major Drivers of Global Melanoma Therapeutics Market
Exhibit 15: Major Challenges in Global Melanoma Therapeutics Market
Exhibit 16: Major Trends in Global Melanoma Therapeutics Market
Exhibit 17: BMS: Global Revenue 2009-2012 (US$ million)
Exhibit 18: BMS: Revenue of Yervoy in US 2011-2014 (US$ million)
Exhibit 19: Merck: YoY Revenue 2010-2013 (US$ billion)
Exhibit 20: Roche: Pharmaceutical Sales by Therapeutic Area 2013
Exhibit 21: Segmentation of Global Melanoma Therapeutics Market by Vendor 2014
Exhibit 22: Bristol-Myers Squibb: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 23: Bristol-Myers Squibb: Revenue by Geographical Segmentation 2013
Exhibit 24: Business Segmentation of Roche 2013
Exhibit 25: Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 26: Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 27: Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 28: Merck: Business Segmentation by Revenue 2013
Exhibit 29: Merck: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 30: Merck: Sales by Geography 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.